Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorNanjing First Hospital, Nanjing Medical University
About this trial
EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and/or after endovascular treatment. The candidate circRNA/lncRNA/miRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 18 years or older
Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan
Within 24 hours of symptom onset and treat with endovascular therapy
Good performance status
Disqualifiers
a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
Trial population
There will be 5 AIS patients, whose data before and after endovascular treatment will be applied for sequencing the differentiated expression pattern and constraction of diagnosis and predictive models of circRNA/lncRNA/miRNA from the circulating blood. There will be 300 AIS patients, whose data will be applied for validation of such diagnosis and predictive models and investigated the effect of non-coding RNA on immune status after endovascular treatment.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Sequencing of circRNA/lncRNA/miRNA
GeneticNext generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
Treatment groups
300 Participants
are divided into 2 treatment groupsGroup A: AIS before EVT group1 intervention
Group B: AIS after EVT group1 intervention
Trial outcomes
Primary outcomes
1
Differential expression pattern of circRNA/lncRNA/miRNA in acute ischemic stroke patients before and after endovascular treatment
Differential expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) will be compared in acute ischemic stroke patients before and after endovascular treatment, thus candidate circRNA/lncRNA/miRNA will be verified as biomarkers and regulators for progression and prognosis of acute ischemic stroke with endovascular treatment.
Time frame
90 daysSecondary outcomes
1
Prognostic value of circRNA/miRNA/lncRNA in acute ischemic stroke with endovascular treatment
The prognosis of AIS patients will be analyzed between differential expressed candidate circRNA/lncRNA/miRNA after they have endovascular treatment.
Time frame
90 days2
Correlation of circRNA/lncRNA/miRNA and inflammatory factors in acute ischemic stroke with endovascular treatment
Correlation of circRNA/lncRNA/miRNA and inflammatory factors in acute ischemic stroke before and after endovascular treatment will be explored.
Time frame
90 days3
Correlation of circRNA/lncRNA/miRNA and stroke-associated infection
Correlation of circRNA/lncRNA/miRNA and stroke-associated infection will be explored in acute ischemic stroke with endovascular treatment.
Time frame
90 days4
Dynamic changes of circRNA/lncRNA/miRNA during the follow-up period
Dynamic changes of circRNA/lncRNA/miRNA will be explored after endovascular therapy during the follow-up period
Time frame
90 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Nanjing First Hospital, Nanjing Medical University
Lead sponsor
Zhongda Hospital
Collaborator
Source ClinicalTrials.gov